{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:27:37Z","timestamp":1768004857477,"version":"3.49.0"},"reference-count":57,"publisher":"Informa UK Limited","issue":"9","funder":[{"name":"Department of Science and Technology, Centre for Policy Research (DST-CPR), Government of India","award":["DST\/PRC\/CPR-04\/2014"],"award-info":[{"award-number":["DST\/PRC\/CPR-04\/2014"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Technology Analysis & Strategic Management"],"published-print":{"date-parts":[[2023,9,2]]},"DOI":"10.1080\/09537325.2021.1994139","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T10:13:29Z","timestamp":1635243209000},"page":"1145-1160","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Rising biosimilars in the Indian biopharmaceutical industry: emerging challenges and way forward"],"prefix":"10.1080","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6625-1940","authenticated-orcid":false,"given":"Pallavi","family":"Singh","sequence":"first","affiliation":[{"name":"DST-Centre for Policy Research, Babasaheb Bhimrao Ambedkar (Central) University, Lucknow, India"}]},{"given":"Pranav N.","family":"Desai","sequence":"additional","affiliation":[{"name":"Centre for Research in Environment, Science and Technology Policy (CREST) and Centre for Studies in Science Policy, Jawaharlal Nehru University, New Delhi, India"}]},{"given":"Venkatesh","family":"Dutta","sequence":"additional","affiliation":[{"name":"DST-Centre for Policy Research, Babasaheb Bhimrao Ambedkar (Central) University, Lucknow, India"},{"name":"Department of Environmental Science, School of Environmental Science, Babasaheb Bhimrao Ambedkar (Central) University, Lucknow, India"}]}],"member":"301","published-online":{"date-parts":[[2021,10,26]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1007\/s10295-019-02216-z"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"CIT0004","unstructured":"BIOCON. 2020. \u201cBiocon and Mylan Win Patent Litigation Asserted by Sanofi for Insulin Gargline Device Patent in US.\u201d https:\/\/www.biocon.com\/biocon-mylan-win-patent-litigation-asserted-by-sanofi-for-insulin-glargine-device-patent-in-u-s\/."},{"key":"CIT0005","unstructured":"BIRAC and ABLE. 2019. \u201cIndia: The Emerging Hub for Biologics and Biosimilars.\u201d Biotechnology Industry Research Assistance Council (BIRAC) and Association of Biotechnology Led Enterprise (ABLE), Special Report. http:\/\/ableindia.in\/manage\/images\/resourceuploads\/_India%20The%20emerging%20hub%20for%20Biologics%20and%20Biosimilars.pdf."},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-99680-6_2"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1177\/2042098618790442"},{"key":"CIT0008","unstructured":"CDER, CBER. 2017. Nonproprietary Naming of Biological Products Guidance for Industry. https:\/\/www.fda.gov\/files\/drugs\/published\/Nonproprietary-Naming-of-Biological-Products-Guidance-for-Industry.pdf."},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.econmod.2008.10.004"},{"key":"CIT0010","first-page":"53","volume":"23","author":"Chaturvedi S.","year":"2012","journal-title":"Economic and Political Weekly"},{"key":"CIT0011","unstructured":"Chen, Y., A. Lehmann, and J. S. Silva. 2019. \u201cWhat\u2019s Next for Biosimilars in Emerging Markets.\u201d McKinsey and Company Report. https:\/\/www.mckinsey.com\/industries\/pharmaceuticals-and-medical-products\/our-insights\/whats-next-for-biosimilars-in-emerging-markets."},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"CIT0013","unstructured":"Deloitte. 2015. \u201cWinning with Biosimilars: Opportunities in Global Markets.\u201d www.deloitte.com\/us\/globalbiosimilars."},{"key":"CIT0014","unstructured":"Desai, P. N. 2014. \u201cMapping Foresight Activities in the Indian Biotechnology Innovation System.\u201d Report Submitted to the National Science, Technology Management Information System (NSTMIS) Division, Department of Science and Technology, Government of India, New Delhi."},{"key":"CIT0015","first-page":"3","volume":"18","author":"Desai P. N.","year":"2016","journal-title":"Asian Biotechnology and Development Review"},{"key":"CIT0016","volume-title":"Directorate General of Commercial Intelligence and Statistics, Exim Data (Goods)","author":"DGCIS","year":"2021"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00395-w"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16102"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-019-01401-5"},{"key":"CIT0020","unstructured":"European Medicines Agency (EMA). 2006. \u201cGuideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues.\u201d EMA: London, UK; EMEA\/CHMP\/BMWP\/42832."},{"key":"CIT0021","unstructured":"European Medicines Agency (EMA). 2014. \u201cGuideline on Similar Biological Medicinal Products Containing Biotechnology Derived Proteins as Active Substance: Non-Clinical and Clinical Issues.\u201d https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf."},{"key":"CIT0022","unstructured":"GaBI. 2017. \u201cIndia Updates it Similar Biologics Guidelines.\u201d Generics and Biosimilars Initiative Journal. http:\/\/www.gabionline.net\/Guidelines\/India-updates-its-similar-biologics-guidelines."},{"key":"CIT0023","unstructured":"GaBI. 2018. \u201cSimilar Biologics Approved and Marketed in India.\u201d Generics and Biosimilars Initiative Journal. http:\/\/www.gabionline.net\/Biosimilars\/General\/Similar-biologics-approved-and-marketed-in-India."},{"key":"CIT0024","unstructured":"GaBI. 2019. \u201cCopy Biologics Approved in China.\u201d Generics and Biosimilars Initiative Journal. http:\/\/www.gabionline.net\/Biosimilars\/General\/Copy-biologicals-approved-in-China."},{"key":"CIT0025","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5639\/gabij.2020.0902.011","volume":"9","author":"GaBI","year":"2020","journal-title":"Generics and Biosimilars Initiative Journal"},{"key":"CIT0026","unstructured":"GaBI. 2020b. \u201cNon-Originator Biologicals Approved in Russia.\u201d Generics and Biosimilars Initiative Journal. https:\/\/www.gabionline.net\/biosimilars\/general\/Non-originator-biologicals-approved-in-Russia."},{"key":"CIT0027","unstructured":"GaBI. 2020c. \u201cSouth Africa Approves First Non-Originator Biological.\u201d Generics and Biosimilars Initiative Journal. https:\/\/www.gabionline.net\/biosimilars\/news\/South-Africa-approves-first-non-originator-biological."},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1108\/EBR-11-2018-0203"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2017.026062"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00377-y"},{"key":"CIT0031","unstructured":"IBEF. 2021. Indian Pharmaceutical Industry. India Brand Equity Foundation, Ministry of Commerce and Industry, Government of India. https:\/\/www.ibef.org\/industry\/pharmaceutical-india.aspx."},{"key":"CIT0032","unstructured":"ICH. 2019. \u201cThe International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH).\u201d Harmonization for Better Life. Accessed October 21, 2019. https:\/\/www.ich.org\/page\/mission."},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0684-9"},{"key":"CIT0034","unstructured":"Jeremias, S. 2020. India Works on Guidelines for Biological Products. https:\/\/www.centerforbiosimilars.com\/news\/part-1-india-must-aim-for-global-standards-in-biosimilar-development."},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1016\/j.techfore.2018.09.020"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1080\/09537325.2016.1276283"},{"key":"CIT0037","first-page":"2132","volume":"4","author":"Kanase S. J.","year":"2013","journal-title":"International Journal of Pharmaceutical Sciences and Research"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1080\/713688318"},{"key":"CIT0040","unstructured":"LexOrbis. 2020. Trends in Biopharma and Biosimilar Patents in India https:\/\/www.lexorbis.com\/trends-in-biopharma-and-biosimilar-patents-in-india\/."},{"key":"CIT0041","first-page":"321","volume":"16","author":"Mahajan M. M.","year":"2011","journal-title":"Journal of Intellectual Property Rights"},{"key":"CIT0042","unstructured":"Markets and Markets. 2019. \u201cBiosimilars Market Worth $ 71.97 billion by 2027, at a CAGR of 32.1%.\u201d https:\/\/www.marketsandmarkets.com\/PressReleases\/global-biosimilars-product-market-worth-19.4-billion-by-2014.asp."},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2016.06.003"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.21786\/bbrc\/14.1\/7"},{"key":"CIT0045","unstructured":"PWC. 2015. Pricewaterhouse Coopers (PWC) Health Research Institute, Top Health Industry Issues of 2016: Enter the Biosimilars. pwchk.com\/en\/people-and-organization\/hc-top-issues-10-jun2016.pdf."},{"issue":"4","key":"CIT0046","first-page":"17","volume":"15","author":"Rader A. R.","year":"2017","journal-title":"BioProcess International"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-021-00395-8"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1285"},{"key":"CIT0049","unstructured":"Sharma, S. 2015. \u201cGrowth of Biosimilars: Implications for Safety and Risk Management.\u201d Contract Pharma. https:\/\/www.contractpharma.com\/issues\/2015-09-01\/view_features\/growth-of-biosimilars-implications-for-safety-and-risk-management."},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-015-0124-7"},{"key":"CIT0051","unstructured":"Statista. 2021. \u201cR&D Spending of Leading Indian Pharmaceutical Companies in Financial year 2020.\u201d https:\/\/www.statista.com\/statistics\/1128053\/india-randd-spending-by-top-indian-pharmaceutical-companies\/."},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195012"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1007\/s11846-016-0218-8"},{"key":"CIT0054","volume-title":"Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs)","author":"WHO","year":"2009"},{"key":"CIT0055","unstructured":"WIPO. 2021. World Intellectual Property Organisation (WIPO). Patent Publications by Technology, WIPO IP Statistics Data Centre. https:\/\/www3.wipo.int\/ipstats\/IpsStatsResultvalue."},{"key":"CIT0056","unstructured":"Wolfson, E. 2013. \u201cJumping Off the Patent Cliff: Are Biosimilars Ready to Take the Plunge?\u201d Healthline. http:\/\/www.healthline.com\/health-news\/are-biosimilarsready-for-prime-time-020613."},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0216-7"}],"container-title":["Technology Analysis & Strategic Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/09537325.2021.1994139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T08:35:02Z","timestamp":1691397302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09537325.2021.1994139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,26]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,2]]}},"alternative-id":["10.1080\/09537325.2021.1994139"],"URL":"https:\/\/doi.org\/10.1080\/09537325.2021.1994139","relation":{},"ISSN":["0953-7325","1465-3990"],"issn-type":[{"value":"0953-7325","type":"print"},{"value":"1465-3990","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ctas20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ctas20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-05-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}